Mechanistic Insights into the Antibiofilm Activity of Simvastatin and Lovastatin against Bacillus subtilis
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Nidhi Verma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Central University of Rajasthan, Kishangarh, Ajmer 305801, Rajasthan, India. Hauptthemen laut MEDLINE: Simvastatin, Bacillus subtilis, Biofilms, Lovastatin. Die Arbeit nennt 67 Literaturangaben. Gefördert von: University Grants Commission, Science and Engineering Research Board.
Abstract (Originalsprache)
Statins have been reported for diverse pleiotropic activities, including antimicrobial and antibiofilm. However, due to the limited understanding of their mode of action, none of the statins have gained approval for antimicrobial or antibiofilm applications. In a recent drug repurposing study, we observed that two statins (i.e., Simvastatin and Lovastatin) interact stably with TasA(28-261), the principal extracellular matrix protein of Bacillus subtilis, and also induce inhibition of biofilm formation. Nevertheless, the underlying mechanism remained elusive. In the present study, we examined the impact of these statins on the physiological activity of TasA(28-261), specifically its interaction with TapA(33-253) and aggregation into the amyloid-like structure using purified recombinant TasA(28-261) and TapA(33-253) in amyloid detection-specific in vitro assays (i.e., CR binding and ThT staining assays). Results revealed that both statins interfered with amyloid formation by the TasA(28-261)-TapA(33-253) complex, while neither statin inhibited amyloid formation by lysozyme, a model amyloid-forming protein. Moreover, neither statin significantly altered the expressions of terminal regulatory genes (viz, sinR, sinI) and terminal effector genes (viz, tasA, tapA, and bslA) involved in biofilm formation by B. subtilis. While the intricate interplay between Simvastatin and Lovastatin with the diverse molecular constituents of B. subtilis biofilm remains to be elucidated conclusively, the findings obtained during the present study suggest that the underlying mechanism for Simvastatin- and Lovastatin-mediated inhibition of B. subtilis biofilm formation is manifested by interfering with the aggregation and amyloid formation by TasA(28-261)-TapA(33-253). These results represent one of the first experimental evidence for the underlying mechanism of antibiofilm activity of statins and offer valuable directions for future research to harness statins as antibiofilm therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Central University of Rajasthan, Kishangarh, Ajmer 305801, Rajasthan, India.
- Department of Biochemistry, Central University of Rajasthan, Kishangarh, Ajmer 305801, Rajasthan, India.
ORCID-Profile: Janmejay Pandey
Förderung
- University Grants Commission
- Science and Engineering Research Board
Zitieren
APA
Verma, N., Bajiya, M., Dolhey, R., Surabhi, Yadav, A. S., Chaudhary, C., Meena, D., Arya, H., Bhatt, T. K., Yadav, J. K., Shukla, J. N., Swaroop, S., & Pandey, J. (2025). Mechanistic Insights into the Antibiofilm Activity of Simvastatin and Lovastatin against Bacillus subtilis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00191
Vancouver
Verma N, Bajiya M, Dolhey R, Surabhi, Yadav AS, Chaudhary C, et al. Mechanistic Insights into the Antibiofilm Activity of Simvastatin and Lovastatin against Bacillus subtilis. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00191
BibTeX
@article{Verma2025,
author = {Verma, Nidhi and Bajiya, Mamta and Dolhey, Ragini and Surabhi and Yadav, Abhishek Singh and Chaudhary, Chhavi and Meena, Dhankesh and Arya, Hemant and Bhatt, Tarun K and Yadav, Jay Kant and Shukla, Jayendra Nath and Swaroop, Shiv and Pandey, Janmejay},
title = {Mechanistic Insights into the Antibiofilm Activity of Simvastatin and Lovastatin against Bacillus subtilis},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00191}
}
EUVIMED